Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant with ChemoRT in Cisplatin-Ineligible Head and Neck Cancer
NCT06110195Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xevinapant in squamous cell carcinoma of the head and neck (HNSCC) (5 arms), sponsored by University of Chicago. Primary endpoint: Best safe dose of xevinapant when given in combination with radiation and chemotherapy at 21 days. Started Jan 2024; status: terminated.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06110195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110195.